Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center Open Label Single Arm Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Trial Profile

A Multi-Center Open Label Single Arm Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Suspended
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Carboplatin (Primary) ; Palbociclib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Dec 2018 Status changed from recruiting to suspended.
    • 21 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 06 Sep 2017 Planned initiation date changed from 1 Sep 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top